456 related articles for article (PubMed ID: 20215977)
21. Effects of postmenopausal hormone therapy every day and every other day on lipid levels according to difference in body mass index.
Yasui T; Umino Y; Takikawa M; Uemura H; Kuwahara A; Matsuzaki T; Maegawa M; Furumoto H; Miura M; Irahara M
Menopause; 2005 Mar; 12(2):223-31. PubMed ID: 15772571
[TBL] [Abstract][Full Text] [Related]
22. Combination therapy of low-dose medroxyprogesterone acetate and oral estrogen does not affect endothelial function in the forearms of postmenopausal women.
Sanada M; Higashi Y; Nakagawa K; Tsuda M; Kodama I; Nagai N; Chayama K; Ohama K
Menopause; 2002; 9(5):360-6. PubMed ID: 12218725
[TBL] [Abstract][Full Text] [Related]
23. Effects of different hormone therapies on breast pain in recently postmenopausal women: findings from the Mayo Clinic KEEPS breast pain ancillary study.
Files JA; Miller VM; Cha SS; Pruthi S
J Womens Health (Larchmt); 2014 Oct; 23(10):801-5. PubMed ID: 25268853
[TBL] [Abstract][Full Text] [Related]
24. Hormone replacement therapy to improve left ventricular diastolic functions in healthy postmenopausal women.
Yildirir A; Yarali H; Kabakci G; Aybar F; Akgul E; Bukulmez O
Int J Gynaecol Obstet; 2001 Dec; 75(3):273-8. PubMed ID: 11728489
[TBL] [Abstract][Full Text] [Related]
25. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques.
Cline JM; Soderqvist G; von Schoultz E; Skoog L; von Schoultz B
Am J Obstet Gynecol; 1996 Jan; 174(1 Pt 1):93-100. PubMed ID: 8572040
[TBL] [Abstract][Full Text] [Related]
26. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
[TBL] [Abstract][Full Text] [Related]
27. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
Modena MG; Sismondi P; Mueck AO; Kuttenn F; Lignières Bd; Verhaeghe J; Foidart JM; Caufriez A; Genazzani AR;
Maturitas; 2005 Sep; 52(1):1-10. PubMed ID: 15963666
[TBL] [Abstract][Full Text] [Related]
28. Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease.
Yeboah J; Klein K; Brosnihan B; Reboussin D; Herrington DM
Menopause; 2008; 15(6):1060-4. PubMed ID: 18521047
[TBL] [Abstract][Full Text] [Related]
29. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C
Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257
[TBL] [Abstract][Full Text] [Related]
30. Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen.
Modena MG; Bursi F; Fantini G; Cagnacci A; Carbonieri A; Fortuna A; Rossi R
Am J Med; 2002 Sep; 113(4):331-4. PubMed ID: 12361820
[No Abstract] [Full Text] [Related]
31. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo.
Murkes D; Lalitkumar PG; Leifland K; Lundström E; Söderqvist G
Gynecol Endocrinol; 2012 Oct; 28 Suppl 2():12-5. PubMed ID: 22834417
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.
Santoro N; Allshouse A; Neal-Perry G; Pal L; Lobo RA; Naftolin F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Dowling NM; Dunn M; Gleason CE; Hodis HN; Isaac B; Magnani M; Manson JE; Miller VM; Taylor HS; Wharton W; Wolff E; Zepeda V; Harman SM
Menopause; 2017 Mar; 24(3):238-246. PubMed ID: 27779568
[TBL] [Abstract][Full Text] [Related]
33. Effects of estrogen with and without progestin on urinary incontinence.
Hendrix SL; Cochrane BB; Nygaard IE; Handa VL; Barnabei VM; Iglesia C; Aragaki A; Naughton MJ; Wallace RB; McNeeley SG
JAMA; 2005 Feb; 293(8):935-48. PubMed ID: 15728164
[TBL] [Abstract][Full Text] [Related]
34. Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?
Falk RT; Manson JE; Barnabei VM; Anderson GL; Brinton LA; Rohan TE; Cauley JA; Chen C; Coburn SB; Pfeiffer RM; Reding KW; Sarto GE; Wentzensen N; Chlebowski RT; Xu X; Trabert B
Int J Cancer; 2019 Feb; 144(4):730-740. PubMed ID: 30183089
[TBL] [Abstract][Full Text] [Related]
35. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
[TBL] [Abstract][Full Text] [Related]
36. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial.
Hlatky MA; Boothroyd D; Vittinghoff E; Sharp P; Whooley MA;
JAMA; 2002 Feb; 287(5):591-7. PubMed ID: 11829697
[TBL] [Abstract][Full Text] [Related]
37. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
[TBL] [Abstract][Full Text] [Related]
38. Effect of hormone replacement therapy on serum levels of tumor markers in healthy postmenopausal women.
Cengiz B; Atabekoglu C; Cetinkaya E; Cengiz SD
Maturitas; 2003 Dec; 46(4):301-6. PubMed ID: 14625127
[TBL] [Abstract][Full Text] [Related]
39. The Women's Health Initiative estrogen plus progestin trial: the study and how it changes our practice.
Hendrix SL
J Am Osteopath Assoc; 2003 Feb; 103(2 Suppl 2):S3-5. PubMed ID: 12625631
[No Abstract] [Full Text] [Related]
40. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
